JP2024528986A - Hpk1アンタゴニスト及びその使用 - Google Patents

Hpk1アンタゴニスト及びその使用 Download PDF

Info

Publication number
JP2024528986A
JP2024528986A JP2024506668A JP2024506668A JP2024528986A JP 2024528986 A JP2024528986 A JP 2024528986A JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024528986 A JP2024528986 A JP 2024528986A
Authority
JP
Japan
Prior art keywords
cancer
compound
nitrogen
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528986A5 (cg-RX-API-DMAC7.html
Inventor
ニール カイラ,
イアン リニー,
スチュアート ウォード,
グラント ウィシャート,
ベン ウィッタカー,
アレクサンドル コート,
ジェレミー ロバート グリーンウッド,
アバ レフラー,
ダニエル エル. セヴェランス,
スティーブン ケー. アルバネーゼ,
Original Assignee
ニンバス サターン, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニンバス サターン, インコーポレイテッド filed Critical ニンバス サターン, インコーポレイテッド
Publication of JP2024528986A publication Critical patent/JP2024528986A/ja
Publication of JP2024528986A5 publication Critical patent/JP2024528986A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024506668A 2021-08-03 2022-08-03 Hpk1アンタゴニスト及びその使用 Pending JP2024528986A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163203890P 2021-08-03 2021-08-03
US63/203,890 2021-08-03
US202163264749P 2021-12-01 2021-12-01
US63/264,749 2021-12-01
PCT/US2022/074455 WO2023015199A1 (en) 2021-08-03 2022-08-03 Hpk1 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2024528986A true JP2024528986A (ja) 2024-08-01
JP2024528986A5 JP2024528986A5 (cg-RX-API-DMAC7.html) 2025-08-13

Family

ID=85156431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506668A Pending JP2024528986A (ja) 2021-08-03 2022-08-03 Hpk1アンタゴニスト及びその使用

Country Status (4)

Country Link
US (1) US20250011331A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024528986A (cg-RX-API-DMAC7.html)
WO (1) WO2023015199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023160577A1 (zh) * 2022-02-23 2023-08-31 正大天晴药业集团股份有限公司 含有吡咯啉酮的稠合双环化合物
CN119301123B (zh) * 2022-06-10 2025-08-29 贝达药业股份有限公司 Hpk1抑制剂及其在医药上的应用
WO2024078448A1 (zh) * 2022-10-10 2024-04-18 珠海宇繁生物科技有限责任公司 一种hpk1激酶抑制剂及其制备方法和应用
WO2025021181A1 (zh) * 2023-07-26 2025-01-30 正大天晴药业集团股份有限公司 取代的吡咯啉酮化合物
WO2025096666A1 (en) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Solid forms of hpk1 antagonists
WO2026072991A1 (en) * 2024-09-26 2026-04-02 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020100027A1 (en) * 2018-11-15 2020-05-22 Pfizer Inc. 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
JP2021502356A (ja) * 2017-11-06 2021-01-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hpk1阻害剤として有用なイソフラノン化合物
WO2021050964A1 (en) * 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008047831A1 (ja) * 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
KR101846475B1 (ko) * 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
EP3596075B1 (en) * 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
US11453681B2 (en) * 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4168411A4 (en) * 2020-06-22 2024-07-24 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING FUNCTION IN P53 MUTANTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502356A (ja) * 2017-11-06 2021-01-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hpk1阻害剤として有用なイソフラノン化合物
WO2020100027A1 (en) * 2018-11-15 2020-05-22 Pfizer Inc. 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
WO2021050964A1 (en) * 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof

Also Published As

Publication number Publication date
EP4380565A4 (en) 2025-05-21
EP4380565A1 (en) 2024-06-12
WO2023015199A1 (en) 2023-02-09
US20250011331A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
US11679109B2 (en) SMARCA degraders and uses thereof
WO2021127278A1 (en) Irak degraders and uses thereof
WO2020010210A1 (en) Mertk degraders and uses thereof
WO2020251969A1 (en) Smarca degraders and uses thereof
JP2022547719A (ja) Hpk1アンタゴニストおよびその使用
WO2021011868A1 (en) Irak degraders and uses thereof
AU2021240046A1 (en) MDM2 degraders and uses thereof
WO2021011871A1 (en) Mertk degraders and uses thereof
US11926625B2 (en) HPK1 antagonists and uses thereof
EP4294790A1 (en) Smarca degraders and uses thereof
US20250011331A1 (en) Hpk1 antagonists and uses thereof
US12466841B2 (en) Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
EP4288430A1 (en) Gpr84 antagonists and uses thereof
WO2024229393A1 (en) Hpk1 degraders and uses thereof
AU2022417301A1 (en) Oxer1 antagonists and uses thereof
CN117915912A (zh) Hpk1拮抗剂和其用途
EP4646198A1 (en) Mk2 degraders and uses thereof
CN117377673A (zh) Hpk1拮抗剂和其用途
WO2024092011A1 (en) Irak degraders and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260424